MBX Biosciences, Inc. MBX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about MBX Biosciences, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MBX Biosciences, Inc.'s additional paid-in capital?
- MBX Biosciences, Inc. (MBX) reported additional paid-in capital of $686.35M in Q1 2026.
- How has MBX Biosciences, Inc.'s additional paid-in capital changed year-over-year?
- MBX Biosciences, Inc.'s additional paid-in capital increased by 73.0% year-over-year, from $396.75M to $686.35M.
- What is the long-term trend for MBX Biosciences, Inc.'s additional paid-in capital?
- Over 2 years (2023 to 2025), MBX Biosciences, Inc.'s additional paid-in capital has grown at a 1293.9% compound annual growth rate (CAGR), from $3.05M to $593.41M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.